3,712 Shares in West Pharmaceutical Services, Inc. $WST Purchased by United Capital Financial Advisors LLC

United Capital Financial Advisors LLC acquired a new stake in West Pharmaceutical Services, Inc. (NYSE:WST) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 3,712 shares of the medical instruments supplier’s stock, valued at approximately $1,333,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. BlackRock Inc. acquired a new stake in shares of West Pharmaceutical Services during the 2nd quarter valued at approximately $2,387,990,000. State Street Corp boosted its holdings in West Pharmaceutical Services by 2.1% in the second quarter. State Street Corp now owns 3,271,866 shares of the medical instruments supplier’s stock worth $715,884,000 after purchasing an additional 68,330 shares during the period. Artisan Partners Limited Partnership increased its stake in West Pharmaceutical Services by 2.9% during the fourth quarter. Artisan Partners Limited Partnership now owns 2,850,401 shares of the medical instruments supplier’s stock valued at $784,259,000 after purchasing an additional 79,481 shares during the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of West Pharmaceutical Services during the second quarter worth $733,733,000. Finally, Generation Investment Management LLP bought a new position in shares of West Pharmaceutical Services in the 2nd quarter worth about $728,168,000. Institutional investors and hedge funds own 93.90% of the company’s stock.

Analyst Upgrades and Downgrades

WST has been the subject of a number of recent research reports. Morgan Stanley boosted their price objective on shares of West Pharmaceutical Services from $325.00 to $365.00 and gave the company an “equal weight” rating in a research report on Thursday, July 9th. KeyCorp upped their target price on West Pharmaceutical Services from $350.00 to $390.00 and gave the company an “overweight” rating in a report on Thursday, July 2nd. Barclays upgraded West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $310.00 to $400.00 in a research report on Tuesday, June 9th. Stephens restated an “overweight” rating and set a $360.00 price objective on shares of West Pharmaceutical Services in a research note on Tuesday, June 2nd. Finally, TD Cowen reaffirmed a “buy” rating on shares of West Pharmaceutical Services in a research report on Wednesday, July 15th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, West Pharmaceutical Services has an average rating of “Moderate Buy” and an average target price of $368.08.

West Pharmaceutical Services Stock Performance

WST opened at $338.21 on Friday. The business’s 50 day moving average is $350.55 and its 200-day moving average is $303.61. The stock has a market cap of $23.80 billion, a PE ratio of 43.30, a price-to-earnings-growth ratio of 2.36 and a beta of 1.15. The company has a current ratio of 2.82, a quick ratio of 2.12 and a debt-to-equity ratio of 0.07. West Pharmaceutical Services, Inc. has a twelve month low of $223.83 and a twelve month high of $386.00.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings data on Thursday, July 23rd. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.08 by $0.29. The business had revenue of $872.30 million during the quarter, compared to analyst estimates of $839.98 million. West Pharmaceutical Services had a return on equity of 20.11% and a net margin of 16.98%.The business’s revenue for the quarter was up 13.8% compared to the same quarter last year. During the same period in the prior year, the company posted $1.84 EPS. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. On average, analysts predict that West Pharmaceutical Services, Inc. will post 8.93 earnings per share for the current year.

West Pharmaceutical Services Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, August 5th. Investors of record on Wednesday, July 29th were paid a dividend of $0.22 per share. This represents a $0.88 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date was Wednesday, July 29th. West Pharmaceutical Services’s payout ratio is currently 11.27%.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.